NIVF vs TMHC vs DHI vs NTRA vs EXAS

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -6. 9% for D. R. Horton, Inc. (DHI). Taylor Morrison Home Corporation (TMHC) offers the better valuation at 7. 7x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Taylor Morrison Home Corporation (TMHC) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Taylor Morrison Home Corporation (TMHC) is the cheapest at 7.

7x versus D. R. Horton, Inc. at 12. 6x. On forward P/E, Taylor Morrison Home Corporation is actually cheaper at 11. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Taylor Morrison Home Corporation wins at 0. 34x versus D. R. Horton, Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -100. 0% for NewGenIvf Group Limited (NIVF). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus NIVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus NewGenIvf Group Limited's 1. 96β — meaning NIVF is approximately 1529% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -6. 9% for D. R. Horton, Inc. (DHI). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -279. 4% for NewGenIvf Group Limited. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

D.

R. Horton, Inc. (DHI) is the more profitable company, earning 10. 5% net margin versus -9. 7% for NewGenIvf Group Limited — meaning it keeps 10. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMHC leads at 14. 0% versus -21. 4% for NIVF. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Taylor Morrison Home Corporation (TMHC) is the more undervalued stock at a PEG of 0. 34x versus D. R. Horton, Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Taylor Morrison Home Corporation (TMHC) trades at 11. 2x forward P/E versus 582. 8x for Exact Sciences Corporation — 571. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMHC: 24. 0% to $73. 75.

In this comparison, DHI (1.

1% yield) pays a dividend. NIVF, TMHC, NTRA, EXAS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). NewGenIvf Group Limited (NIVF) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, NIVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NIVF (Healthcare) and TMHC (Consumer Cyclical) and DHI (Consumer Cyclical) and NTRA (Healthcare) and EXAS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NIVF is a small-cap quality compounder stock; TMHC is a small-cap deep-value stock; DHI is a mid-cap deep-value stock; NTRA is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock. DHI pays a dividend while NIVF, TMHC, NTRA, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.